The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, Pfizer Obtain Approval for Their Competition Generics for June Listing
February 17, 2012
- Drugstore Chains to Appeal Directly to Public in Support of “Dispensing Point” Services
February 17, 2012
- EC Approves Add’l Indication of CHF for Ion Channel Inhibitor Ivabradine: Ono
February 17, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
- UMN Obtains Worldwide Rights for Norovirus and Rotavirus Combined Vaccine
February 16, 2012
- Pfizer Obtains Approval for Generics of 10 APIs
February 16, 2012
- Maruho Acquires Venture in Bid to Develop US Business Base
February 15, 2012
- Celecox Ranked Top Place in HP Market: RepTrack Survey
February 15, 2012
- MSD Issues Precaution for Gardasil on Syncope, Falls
February 15, 2012
- MSD Cautions against Syncope, Fall after Gardasil Vaccination
February 15, 2012
- Major Pharmacy Chains to Boost Efforts to Raise GE Dispensing Rates Despite Dissatisfaction with Revised Premiums
February 15, 2012
- Altheos Initiates PIIa Trial for ATS907 in the US: Asahi Kasei Pharma
February 14, 2012
- Sawai Wins Patent Lawsuit on Ebastine
February 14, 2012
- Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
- Otsuka HD Director Kimura Anticipates Seroquel Patent Expiry to Impact Abilify
February 14, 2012
- AnGes MG to Seek Return of ¥75 Million Patent Remuneration from Board Member Morishita
February 14, 2012
- Otsuka HD Files Application for Antituberculosis Drug Delamanid in Europe
February 13, 2012
- April-December Pharmaceutical Sales Up 4.1% Driven by Abilify: Otsuka HD
February 13, 2012
- Altheos Begins PIIa Trial for ATS907 in US: Asahi Kasei Pharma
February 13, 2012
- AnGes MG Announces Positive Results from Exploratory Trial of CIN Vaccine
February 13, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…